Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283524047> ?p ?o ?g. }
- W4283524047 endingPage "559" @default.
- W4283524047 startingPage "546" @default.
- W4283524047 abstract "Since 2017, 3 CD19-directed chimeric antigen receptor (CAR) T cell therapies—axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—have been approved for relapsed/refractory aggressive diffuse large B cell lymphoma after 2 lines of therapy. Recently, 3 prospective phase 3 randomized clinical trials were conducted to define the optimal second-line treatment by comparing each of the CAR T cell products to the current standard of care: ZUMA-7 for axicabtagene ciloleucel, BELINDA for tisagenlecleucel, and TRANSFORM for lisocabtagene maraleucel. These 3 studies, although largely addressing the same question, had different outcomes, with ZUMA-7 and TRANSFORM demonstrating significant improvement with CD19 CAR T cells in second-line therapy compared with standard of care but BELINDA not showing any benefit. The US Food and Drug Administration has now approved axicabtagene ciloleucel and lisocabtagene maraleucel for LBCL that is refractory to first-line chemoimmunotherapy or relapse occurring within 12 months of first-line chemoimmunotherapy. Following the reporting of these practice changing studies, here a group of experts convened by the American Society for Transplantation and Cellular Therapy provides a comprehensive review of the 3 studies, emphasizing potential differences, and shares perspectives on what these results mean to clinical practice in this new era of treatment of B cell lymphomas." @default.
- W4283524047 created "2022-06-27" @default.
- W4283524047 creator A5005058090 @default.
- W4283524047 creator A5011030256 @default.
- W4283524047 creator A5021595775 @default.
- W4283524047 creator A5039067043 @default.
- W4283524047 creator A5040504519 @default.
- W4283524047 creator A5051833337 @default.
- W4283524047 creator A5054196868 @default.
- W4283524047 creator A5074706721 @default.
- W4283524047 date "2022-09-01" @default.
- W4283524047 modified "2023-10-14" @default.
- W4283524047 title "Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy" @default.
- W4283524047 cites W1653498040 @default.
- W4283524047 cites W1976564639 @default.
- W4283524047 cites W1988817337 @default.
- W4283524047 cites W1997353354 @default.
- W4283524047 cites W2020869508 @default.
- W4283524047 cites W2029421916 @default.
- W4283524047 cites W2034892179 @default.
- W4283524047 cites W2050491407 @default.
- W4283524047 cites W2058056848 @default.
- W4283524047 cites W2082708772 @default.
- W4283524047 cites W2097145287 @default.
- W4283524047 cites W2119147717 @default.
- W4283524047 cites W2126021331 @default.
- W4283524047 cites W2130997237 @default.
- W4283524047 cites W2133345449 @default.
- W4283524047 cites W2144431977 @default.
- W4283524047 cites W2150587745 @default.
- W4283524047 cites W2254037519 @default.
- W4283524047 cites W2300560420 @default.
- W4283524047 cites W2346332363 @default.
- W4283524047 cites W2532606512 @default.
- W4283524047 cites W2556342759 @default.
- W4283524047 cites W2564775203 @default.
- W4283524047 cites W2598700764 @default.
- W4283524047 cites W2605938954 @default.
- W4283524047 cites W2744261860 @default.
- W4283524047 cites W2773804840 @default.
- W4283524047 cites W2788584021 @default.
- W4283524047 cites W2800595080 @default.
- W4283524047 cites W2805523469 @default.
- W4283524047 cites W2903062212 @default.
- W4283524047 cites W2903225254 @default.
- W4283524047 cites W2905654445 @default.
- W4283524047 cites W2912692587 @default.
- W4283524047 cites W2933778904 @default.
- W4283524047 cites W2944689312 @default.
- W4283524047 cites W2948047060 @default.
- W4283524047 cites W2953936851 @default.
- W4283524047 cites W2967884832 @default.
- W4283524047 cites W2969216121 @default.
- W4283524047 cites W2975143341 @default.
- W4283524047 cites W2980400657 @default.
- W4283524047 cites W2981626013 @default.
- W4283524047 cites W2983077705 @default.
- W4283524047 cites W2986232810 @default.
- W4283524047 cites W2987877618 @default.
- W4283524047 cites W3001726414 @default.
- W4283524047 cites W3006331283 @default.
- W4283524047 cites W3007726400 @default.
- W4283524047 cites W3007888754 @default.
- W4283524047 cites W3009748032 @default.
- W4283524047 cites W3011327279 @default.
- W4283524047 cites W3015094526 @default.
- W4283524047 cites W3017021401 @default.
- W4283524047 cites W3032130826 @default.
- W4283524047 cites W3034162969 @default.
- W4283524047 cites W3039798010 @default.
- W4283524047 cites W3046970338 @default.
- W4283524047 cites W3048777956 @default.
- W4283524047 cites W3080764569 @default.
- W4283524047 cites W3082855561 @default.
- W4283524047 cites W3084913831 @default.
- W4283524047 cites W3088453061 @default.
- W4283524047 cites W3089727781 @default.
- W4283524047 cites W3090501571 @default.
- W4283524047 cites W3095173757 @default.
- W4283524047 cites W3096139078 @default.
- W4283524047 cites W3096548119 @default.
- W4283524047 cites W3097467929 @default.
- W4283524047 cites W3112524531 @default.
- W4283524047 cites W3116008789 @default.
- W4283524047 cites W3116401648 @default.
- W4283524047 cites W3116823573 @default.
- W4283524047 cites W3120738879 @default.
- W4283524047 cites W3121871507 @default.
- W4283524047 cites W3126646408 @default.
- W4283524047 cites W3132778321 @default.
- W4283524047 cites W3135175412 @default.
- W4283524047 cites W3144369660 @default.
- W4283524047 cites W3159464314 @default.
- W4283524047 cites W3162374648 @default.
- W4283524047 cites W3165864905 @default.
- W4283524047 cites W3169727834 @default.
- W4283524047 cites W3172673272 @default.
- W4283524047 cites W3174918603 @default.